Erschienen in:
Open Access
01.12.2020 | Correction
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
verfasst von:
Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2020
Correction to: Breast Cancer Res (2020) 22:4
https://doi.org/10.1186/s13058-019-1243-8
After publication of the original article [
1], the authors identified two errors in the Author details:
1.Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley’s affiliation in addition to Tennessee Oncology.
2.Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.